13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000200406
Total reported value
$798.7M
$798.7M
20 檔
32.6%
In Q4 2024, Johnson & Johnson's U.S. equity holdings reached a combined market value of $798.7M, distributed across 20 disclosed stock positions.
In Q4 2024, Johnson & Johnson adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 1 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including PTGX, CVRX, RAPP) accounted for 32.6% of total reported equity market value during Q4 2024.
Top New Position Initiated
LYEL
市值: $526.9K
Top Position Liquidated / Trimmed
CLSDUSD
前期市值: $104.8K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 24.48% | -1.98% | — | |
| 2 | CVRX | Cvrx Inc | Stock-Other | 13.46% | -3.25% | — | |
| 3 | RAPP | Rapport Therapeutics Inc | Stock-Other | 11.48% | +0.75% | — | |
| 4 | MGTX | MeiraGTx Holdings plc | Stock-Other | 10.47% | +2.41% | — | |
| 5 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 7.51% | +0.10% | — | |
| 6 | PRCT | Procept Biorobotics CORP | Stock-Other | 7.46% | -0.36% | — | |
| 7 | LEGN | Legend Biotech Corp-adr | Stock-Other | 6.86% | +0.69% | — | |
| 8 | NMRA | Neumora Therapeutics Inc | Stock-Other | 5.08% | -0.16% | — | |
| 9 | XNCR | Xencor Inc | Stock-Other | 4.45% | +0.13% | — | |
| 10 | NBTX | Nanobiotix SA - Adr | Stock-Other | 4.18% | -0.06% | — | |
| 11 | FATE | Fate Therapeutics Inc | Stock-Other | 1.44% | +0.52% | — | |
| 12 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.21% | — | — | |
| 13 | ✓ | Rallybio CORP | Stock-Other | 0.90% | — | — | |
| 14 | VOR | Vor Biopharma Inc. | Stock-Other | 0.31% | — | — | |
| 15 | NNOX | Nano-X Imaging Ltd. | Stock-Other | 0.30% | -0.03% | EXIT | |
| 16 | LAB | Standard Biotools Inc | Stock-Other | 0.14% | -0.01% | — | |
| 17 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 0.14% | — | — | |
| 18 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.09% | — | — | |
| 19 | ✓ | Biomx Inc | Stock-Other | 0.02% | — | -49.63% | |
| 20 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CVRX | Cvrx Inc | +5% | — | Unchanged |
| 2 | MGTX | MeiraGTx Holdings plc | +4% | — | Unchanged |
| 3 | XNCR | Xencor Inc | +0.9% | — | Unchanged |
| 4 | PRCT | Procept Biorobotics CORP | +0.8% | — | Unchanged |
| 5 | LYEL | Lyell Immunopharma, Inc. | +0.1% | NEW | New buy |
| 6 | VOR | Vor Biopharma Inc. | +0.1% | — | Unchanged |
| 7 | ARWR | Arrowhead Pharmaceuticals In | +0.1% | — | Unchanged |
| 8 | NNOX | Nano-X Imaging Ltd. | +0.1% | — | Unchanged |
| 9 | SENS1GBP | Senseonics Holdings Inc | 0% | — | Unchanged |
| 10 | LAB | Standard Biotools Inc | — | — | Unchanged |
| 11 | CLSDUSD | Clearside Biomedical Inc | 0% | EXIT | Sold out |
| 12 | TORCEUR | Adicet Bio Inc | 0% | — | Unchanged |
| 13 | ✓ | Biomx Inc | 0% | -49.63% | Trim |
| 14 | ✓ | Rallybio CORP | -0.1% | — | Unchanged |
| 15 | RAPP | Rapport Therapeutics Inc | -0.5% | — | Unchanged |
| 16 | NMRA | Neumora Therapeutics Inc | -0.6% | — | Unchanged |
| 17 | PTGX | Protagonist Therapeutics Inc | -1.3% | — | Unchanged |
| 18 | FATE | Fate Therapeutics Inc | -1.3% | — | Unchanged |
| 19 | CTNM | Contineum Therapeutics Inc-a | -1.4% | — | Unchanged |
| 20 | LEGN | Legend Biotech Corp-adr | -2.4% | — | Unchanged |
| 21 | NBTX | Nanobiotix SA - Adr | -3.4% | — | Unchanged |
According to official SEC Form 13F filings, Johnson & Johnson reported a total U.S. public equity portfolio value of $798.7M across 20 disclosed positions in Q4 2024.
During Q4 2024, Johnson & Johnson's top holdings by market value included PTGX (24.5%)、CVRX (13.5%)、RAPP (11.5%). The largest single position, PTGX, represented 24.5% of total portfolio value.
In Q4 2024, Johnson & Johnson made 3 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.